Business Context and Reporting Period
Company: Theriva Biologics, Inc. (TOVX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Event-based report regarding upcoming investor presentations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an informational filing regarding corporate communications and does not contain financial statements or performance data.
Material Changes
No material changes to financial position or operations are reported in this document. The filing serves to announce the distribution of an updated investor presentation.
Guidance, Outlook, and Risks
- Upcoming Events: The Company will conduct several investor presentations over the coming weeks.
- Forward-Looking Statements: The updated presentation (Exhibit 99.1) contains "forward-looking" statements subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
- Management Commentary: No specific operational commentary or guidance is included in the body of this 8-K; details are contained within the attached presentation.
Investor Verification Checklist
- Review Exhibit 99.1 (Presentation of Theriva Biologics, Inc., dated January 2026) for specific forward-looking statements and strategic updates.
- Verify the trading status of Common Stock (TOVX) on NYSE American.
- Confirm the identity of the signatory, Steven A. Shallcross, serving as both Chief Executive Officer and Chief Financial Officer.